Literature DB >> 12391223

Cysteine residues required for the attachment of the light chain in human IgA2.

Koteswara R Chintalacharuvu1, Li J Yu, Nishant Bhola, Kunihiko Kobayashi, Christine Z Fernandez, Sherie L Morrison.   

Abstract

In humans, there are two subclasses of IgA, IgA1 and IgA2, with IgA2 existing as three allotypes, IgA2m(1), IgA2m(2) and IgA2(n). In IgA1, Cys(133) in C(H)1 forms the disulfide bond to the L chain. Our previous studies indicated that in IgA2 lacking Cys(133), a disulfide bond forms between the alpha-chain and the L chain when Cys(220) is followed by Arg(221), but not when Cys(220) is followed by Pro(221), suggesting that the Cys in C(H)1 might be involved in disulfide bonding to the L chain. However, here we show that covalent assembly of the H and L chains in IgA2(n) requires hinge-proximal Cys(241) and Cys(242) in C(H)2 and not Cys(196) or Cys(220) in C(H)1. Using pulse-chase experiments, we have demonstrated that wild-type IgA2(n) with Arg(221) and Cys(241) and Cys(242) assembles through a disulfide-bonded HL intermediate. In contrast, the major intermediate for IgA2 m(1) with Pro(221) assembly was H(2) even though both Cys(241) and Cys(242) were present. Only a small fraction of IgA2 m(1) assembles through disulfide-bonded HL. Overall, our studies indicate that for IgA2 covalent assembly of the H and L chains requires the hinge-proximal cysteines in C(H)2 and that the structure of C(H)1 influences the efficiency with which this covalent bond forms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391223     DOI: 10.4049/jimmunol.169.9.5072

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Cleavage of the human immunoglobulin A1 (IgA1) hinge region by IgA1 proteases requires structures in the Fc region of IgA.

Authors:  Koteswara R Chintalacharuvu; Philip D Chuang; Ashley Dragoman; Christine Z Fernandez; Jiazhou Qiu; Andrew G Plaut; K Ryan Trinh; Françoise A Gala; Sherie L Morrison
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

2.  Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.

Authors:  Stefan Lohse; Christina Brunke; Stefanie Derer; Matthias Peipp; Peter Boross; Christian Kellner; Thomas Beyer; Michael Dechant; Jan G J van der Winkel; Jeanette H W Leusen; Thomas Valerius
Journal:  J Biol Chem       Date:  2012-06-07       Impact factor: 5.157

3.  Structural correlates of mouse IgA allotypes.

Authors:  Julia M Phillips-Quagliata
Journal:  Immunogenetics       Date:  2009-12-15       Impact factor: 2.846

4.  Alternative pathways of disulfide bond formation yield secretion-competent, stable and functional immunoglobulins.

Authors:  Yechiel Elkabetz; Ayala Ofir; Yair Argon; Shoshana Bar-Nun
Journal:  Mol Immunol       Date:  2008-08-09       Impact factor: 4.407

5.  A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.

Authors:  Gerard Ja Rouwendal; Miranda M van der Lee; Saskia Meyer; Karli R Reiding; Jan Schouten; Guy de Roo; David F Egging; Jeanette Hw Leusen; Peter Boross; Manfred Wuhrer; Gijs F Verheijden; Wim H Dokter; Marco Timmers; Ruud Ubink
Journal:  MAbs       Date:  2015-10-06       Impact factor: 5.857

Review 6.  IgA: Structure, Function, and Developability.

Authors:  Patrícia de Sousa-Pereira; Jenny M Woof
Journal:  Antibodies (Basel)       Date:  2019-12-05

Review 7.  3D Structures of IgA, IgM, and Components.

Authors:  Shunli Pan; Noriyoshi Manabe; Yoshiki Yamaguchi
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

8.  Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.

Authors:  Christina Brunke; Stefan Lohse; Stefanie Derer; Matthias Peipp; Peter Boross; Christian Kellner; Thomas Beyer; Michael Dechant; Louise Royle; Li Phing Liew; Jeanette H W Leusen; Thomas Valerius
Journal:  MAbs       Date:  2013 Nov-Dec       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.